Cargando…

Tumor and host characteristics of small cell lung cancer (SCLC) in U.S. community oncology practice

Detalles Bibliográficos
Autores principales:	Richards, Donald, Li, Si G, Anderson, Thomas, Monte, Marc, Ulrich, Brian, Smith, David A, Seetharam, Mahesh, Kaywin, Paul, Page, Ray, Kulig, Kimary, Batenchuk, Cory, Hussein, Maen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2015
Materias:	Poster Presentation
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4645178/ http://dx.doi.org/10.1186/2051-1426-3-S2-P170

Ejemplares similares

SCLC Treatment in the Immuno-Oncology Era: Current Evidence and Unmet Needs
por: Belluomini, Lorenzo, et al.
Publicado: (2022)

Clinicopathological Difference and Survival Impact of Patients with c-SCLC and SCLC
por: Zhang, Chenyue, et al.
Publicado: (2021)

Sonic Hedgehog in SCLC
por: Laukkanen, Mikko O., et al.
Publicado: (2015)

Pathology and Classification of SCLC
por: Raso, Maria Gabriela, et al.
Publicado: (2021)

Physical and Functional Association of the Major Histocompatibility Complex Class I Heavy Chain α3 Domain with the Transporter Associated with Antigen Processing
por: Kulig, Kimary, et al.
Publicado: (1998)

Is transformed small cell lung cancer (SCLC) different from de novo SCLC?
por: Park, Cheol-Kyu, et al.
Publicado: (2019)

What Are the Biomarkers for Immunotherapy in SCLC?
por: Longo, Vito, et al.
Publicado: (2021)

Prophylactic cranial irradiation in SCLC
por: Suwinski, Rafal
Publicado: (2021)

Comparative analysis of machine learning approaches to classify tumor mutation burden in lung adenocarcinoma using histopathology images
por: Sadhwani, Apaar, et al.
Publicado: (2021)

What's New in SCLC? A Review
por: Oronsky, Bryan, et al.
Publicado: (2017)

Understanding SCLC heterogeneity and plasticity in cancer metastasis and chemotherapy resistance: Understanding SCLC heterogeneity and plasticity in metastasis and chemoresistance
por: Jin, Yujuan, et al.
Publicado: (2023)

Identification of response-modulated genetic interactions by sensitivity-based epistatic analysis
por: Batenchuk, Cory, et al.
Publicado: (2010)

Fall DECUS U.S.
por: Anderson, R E
Publicado: (1977)

Geographic disparities in the distribution of the U.S. gynecologic oncology workforce: A Society of Gynecologic Oncology study
por: Ricci, Stephanie, et al.
Publicado: (2017)

Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Arginine Deprivation in SCLC: Mechanisms and Perspectives for Therapy
por: Carpentier, Joséphine, et al.
Publicado: (2022)

Impact of Socioeconomic Factors on Overall Survival in SCLC
por: Roof, Logan, et al.
Publicado: (2022)

“Doing Good” in U.S. Cancer Genomics? Valuation practices across the boundaries of research and care in rural community oncology
por: Darling, Katherine Weatherford, et al.
Publicado: (2022)

Could Somatostatin Enhance the Outcomes of Chemotherapeutic Treatment in SCLC?
por: Domvri, Kalliopi, et al.
Publicado: (2015)

Development and Validation of a Simplified Prognostic Score in SCLC
por: Negre, Elodie, et al.
Publicado: (2020)

Promising Role of Circulating Tumor Cells in the Management of SCLC
por: De Luca, Antonella, et al.
Publicado: (2021)

Correction to: Durvalumab: A Review in Extensive-Stage SCLC
por: Al-Salama, Zaina T.
Publicado: (2021)

Organoids as a Systems Platform for SCLC Brain Metastasis
por: Quaranta, Vito, et al.
Publicado: (2022)

Sino-U.S. Decoupling: The Roles of U.S. Congress
por: Guo, Baogang
Publicado: (2021)

Recruitment practices for U.S. minority and underserved populations in NRG oncology: Results of an online survey()
por: Cook, Elise D., et al.
Publicado: (2018)

Tweet for the cure: A snapshot of Twitter usage by 3 U.S. oncologic professional societies
por: Jhawar, Sachin R., et al.
Publicado: (2017)

Experience with Peroral Endoscopic Myotomy for Achalasia and Spastic Esophageal Motility Disorders at a Tertiary U.S. Center
por: Masadeh, Maen, et al.
Publicado: (2020)

SCLC extensive disease – treatment guidance by extent or/and biology of response?
por: Eckert, Franziska, et al.
Publicado: (2008)

Identification of candidate biomarkers and pathways associated with SCLC by bioinformatics analysis
por: Wen, Pushuai, et al.
Publicado: (2018)

Racial and Other Healthcare Disparities in Patients With Extensive-Stage SCLC
por: Tapan, Umit, et al.
Publicado: (2020)

Killing SCLC: insights into how to target a shapeshifting tumor
por: Sutherland, Kate D., et al.
Publicado: (2022)

Subtype of SCLC Is an Intrinsic and Persistent Feature Through Systemic Treatment
por: Lo, Ying-Chun, et al.
Publicado: (2023)

Demographics of ASTRO Student Members and Potential Implications for Future U.S. Radiation Oncology Workforce Diversity
por: Mattes, Malcolm D., et al.
Publicado: (2021)

Sites of recurrent disease and prognostic factors in SCLC patients treated with radiochemotherapy
por: Bütof, Rebecca, et al.
Publicado: (2017)

Update on the Biology, Management, and Treatment of Small Cell Lung Cancer (SCLC)
por: Saltos, Andreas, et al.
Publicado: (2020)

Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
por: Ready, Neal, et al.
Publicado: (2018)

Circulating Tumor DNA as a Biomarker of Radiographic Tumor Burden in SCLC
por: Smith, Jarrod T., et al.
Publicado: (2020)

Genomic and Transcriptomic Characterization of Relapsed SCLC Through Rapid Research Autopsy
por: Chen, Hui-Zi, et al.
Publicado: (2021)

Successful Treatment of EGFR-Mutant Synchronous SCLC and Lung Adenocarcinoma With Osimertinib
por: Batra, Ullas, et al.
Publicado: (2020)

Survival, Chemotherapy and Chemosensitivity Predicted by CTC Cultured In Vitro of SCLC Patients
por: Ju, Lixia, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_q0gtfs6bpm8d44docor66ncvd6